Impact the pandemic by the new Coronavirus on the consumption profi le of anxiolytics and antidepressants in the Primary Health Care of the Federal District, Brazil

Abstract

The new Coronavirus pandemic provided an increase in psychosocial vulnerability and the aggravation of preexisting pathologies, such as depression and anxiety. This work aimed to evaluate the impact of the
COVID-19 pandemic on the consumption of anxiolytics and antidepressants at UBS 4 in Recanto das Emas – Distrito Federal through an observational, cross-sectional study that analyzed the consumption of anxiolytics and antidepressants in the period between February and August 2019 and 2020, using the average monthly consumption and the number of visits. In addition, information on sex and age was also verified to draw a profile of consumption of these medications. Of the 7 medications evaluated, all showed an increase in consumption in 2020, this being 181.90%, 124.36%, 325.33%, 125%, 12.80%, 22.18% and 6.45 % for fl uoxetine 20 mg, amitriptyline 25 mg, imipramine 25 mg, clomipramine 75 mg, diazepam 5 mg, clonazepam 2 mg and clonazepam 2.5mg/mL respectively. There was a predominance of females and the population aged between 20 and 59 years as major consumers of these drugs. In general, there was a great
impact on the consumption profiles of psychotropic drugs in the period evaluated.